Tomosada Yoshikawa
Director/Board Member chez KLAB INC.
Profil
Tomosada Yoshikawa is an Independent Outside Director at KLab, Inc. since 2018.
He is also a Director & Vice President at SUS Co., Ltd.
since 2018 and a Director at Cross Reality Co., Ltd.
since 2019.
Previously, he served as an Independent Outside Director at tella, Inc. from 2018 to 2019 and as MD, Head-Administration & IR Contact at Taiko Pharmaceutical Co., Ltd.
from 2009 to 2013.
He holds an MBA from Babson College (1999) and an undergraduate degree from Kwansei Gakuin University (1989).
Postes actifs de Tomosada Yoshikawa
| Sociétés | Poste | Début |
|---|---|---|
| KLAB INC. | Director/Board Member | 25/03/2018 |
| SUS CO.,LTD. | Director/Board Member | 01/12/2018 |
| Cross Reality Co., Ltd. | Director/Board Member | 01/09/2019 |
Anciens postes connus de Tomosada Yoshikawa
| Sociétés | Poste | Fin |
|---|---|---|
| TELLA, INC. | Director/Board Member | 27/03/2019 |
| TAIKO PHARMACEUTICAL CO.,LTD. | Director of Finance/CFO | 01/06/2013 |
Formation de Tomosada Yoshikawa
| Babson College | Masters Business Admin |
| Kwansei Gakuin University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| KLAB INC. | Technology Services |
| SUS CO.,LTD. | Commercial Services |
| TAIKO PHARMACEUTICAL CO.,LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Cross Reality Co., Ltd. | |
tella, Inc.
 tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
